Dosing

Once-daily dosing for INGREZZA1

INGREZZA offers once-daily dosing1

INGREZZA can be taken with or without food1

In clinical trials, patients who received INGREZZA were allowed to remain on their stable treatment regimen2

The most common types of concomitant medications were2

  • Antipsychotics (85.5%)
  • Antidepressants (66.5%)
  • Anticholinergics (37.0%)
  • Antiepileptics (35.2%)
  • Anxiolytics (27.7%)
  • ACE inhibitors (25.6%)

Drug interactions

Dosing recommendations for patients with complex medical histories1

MAOIs, monoamine oxidase inhibitors.

Administration information

Continue to make monitoring a routine part of care for patients with tardive dyskinesia (TD)

For patients with increased cardiac risk1 INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

For TD patients with renal impairment1 Dosage adjustment is not necessary for patients with mild to moderate renal impairment (creatinine clearance 30-90 mL/min). INGREZZA does not undergo primary renal clearance. INGREZZA is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min).

For TD patients with hepatic impairment1 Dosage reduction of INGREZZA is recommended for patients with moderate or severe hepatic impairment (Child-Pugh score 7 to 15). Patients with moderate to severe hepatic impairment had higher exposure of INGREZZA and its active metabolite than patients with normal hepatic function. The recommended dose for patients with moderate or severe hepatic impairment is INGREZZA 40 mg once daily.

  • Convenient once-daily dosing

    Once-daily dosing for INGREZZA1

    INGREZZA offers once-daily dosing1

    INGREZZA can be taken with or without food1

    In clinical trials, patients who received INGREZZA were allowed to remain on their stable treatment regimen2

    The most common types of concomitant medications were2

    • Antipsychotics (85.5%)
    • Antidepressants (66.5%)
    • Anticholinergics (37.0%)
    • Antiepileptics (35.2%)
    • Anxiolytics (27.7%)
    • ACE inhibitors (25.6%)
  • Drug interactions

    Drug interactions

    Dosing recommendations for patients with complex medical histories1

    MAOIs, monoamine oxidase inhibitors.
  • Administration information

    Administration information

    Continue to make monitoring a routine part of care for patients with tardive dyskinesia (TD)

    For patients with increased cardiac risk1 INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

    For TD patients with renal impairment1 Dosage adjustment is not necessary for patients with mild to moderate renal impairment (creatinine clearance 30-90 mL/min). INGREZZA does not undergo primary renal clearance. INGREZZA is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min).

    For TD patients with hepatic impairment1 Dosage reduction of INGREZZA is recommended for patients with moderate or severe hepatic impairment (Child-Pugh score 7 to 15). Patients with moderate to severe hepatic impairment had higher exposure of INGREZZA and its active metabolite than patients with normal hepatic function. The recommended dose for patients with moderate or severe hepatic impairment is INGREZZA 40 mg once daily.